GlaxoSmithKline Up 31.2% Since SmarTrend's Buy Recommendation
GSK | Quote | Chart | News | PowerRating -- SmarTrend, our proprietary pattern recognition system, called an Uptrend for GlaxoSmithKline (NYSE:GSK) on May 12, 2009 at $31.94.
Since then, GlaxoSmithKline has returned 31.2% as of today's recent price of $41.90. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
For full details on GlaxoSmithKline (GSK) GSK. GlaxoSmithKline (GSK) has Short Term PowerRatings at TradingMarkets. Details on GlaxoSmithKline (GSK) Short Term PowerRatings is available at This Link.
- Zacks Sell List Highlights: BancorpSouth, Inc., Aetna Inc., GlaxoSmithKline plc and Airgas, Inc. - 02/09/10
- Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results - 02/09/10
- GlaxoSmithKline not to acquire 5% stake in Dr. Reddy's Laboratories - 02/08/10
- Nabi Biopharmaceuticals Completes Another PentaStaph(TM) Milestone - 02/08/10
- Transparency Could Hamper Thought Leader Relationships, Says Cutting Edge Information - 02/08/10
- More News >>


